SAN DIEGO, Nov. 14, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (“Apricus Bio” or the “Company”) (Nasdaq:APRI) announced today the acceptance of an abstract entitled, “Age Group Analysis of a Randomized, Double-blind, Phase 3 study of Femprox®, a Topical Alprostadil Cream with a Novel Transdermal Delivery Technology (Nexact®) for the Treatment of Female Sexual Arousal Disorder (“FSAD”),” as a Highlighted Poster, followed by an oral presentation at the upcoming European Society of Sexual Medicine (“ESSM”) conference taking place in Milan, Italy, December 1-4, 2011.
